[go: up one dir, main page]

AR057145A1 - N-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas con actividad antagonista de receptores ppardelta o ppardelta y ppargamma - Google Patents

N-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas con actividad antagonista de receptores ppardelta o ppardelta y ppargamma

Info

Publication number
AR057145A1
AR057145A1 ARP060104363A ARP060104363A AR057145A1 AR 057145 A1 AR057145 A1 AR 057145A1 AR P060104363 A ARP060104363 A AR P060104363A AR P060104363 A ARP060104363 A AR P060104363A AR 057145 A1 AR057145 A1 AR 057145A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
cycloalkyl
trisubstituted
mono
Prior art date
Application number
ARP060104363A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45219047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057145(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR057145A1 publication Critical patent/AR057145A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Composiciones farmacéuticas que los contienen, procesos de preparacion y usos para el tratamiento y/o la prevencion de trastornos del metabolismo de ácidos grasos y uso de la glucosa como también de trastornos en los que está implicada la resistencia a la insulina y otros trastornos desmielinizantes y neurodegenerativos de los sistemas nerviosos central y periférico. Reivindicacion 1: Compuestos de formula (1), en la que: R1 es alquilo C1-6, alquilenC0-6-cicloalquilo C3-6, alquilenC0-6-O-alquiloC1-6, alquilenC0-6-O-cicloalquiloC3-6, alquilenC0-6-ariloC6-14, alquilenC0-6-heteroariloC5-15, en donde alquilo, alquileno, arilo, heteroarilo y cicloalquilo pueden estar no sustituidos o pueden estar mono, di- o trisustituidos con F, Cl, Br, alquilo C1-6, O-alquiloC1-6, CF3, OCF3, CN, CO-alquiloC1-6, COOalquiloC1-6, CON(alquilenC0-6-H)(alquilenC0-6-H), S(O)malquiloC1-6; R2, R3 son, de modo independiente H, halogeno, alquilo C1-6, alquilenC0-4-O-alquilenC0-4-H, CN, COOalquiloC1-6, CON(alquilenC0-6-H)(alquilenC0-6-H), S(O)malquiloC1-6, en donde alquilo y alquileno son no sustituidos o mono, di- o trisustituidos con F; A es arilo C6-14 o heteroarilo C3-12; R4, R5 son, de modo independiente, H, alquilo C1-6, CN, CO-alquiloC1-6, COO-alquiloC1-6, CON(alquilenC0-6-H)(alquilenC0-6-H), S(O)malquiloC1-6, N(alquilenC0-6-H)(alquilenC0-6-H), N(alquilenC0-6-H)-CO-alquiloC1-6, N(alquilenC0-6-H)-CO-alquiloC1-6, halogeno, alquilenC0-6-O-alquilenC0-6-H, alquilenC0-6-O- ariloC6-14, SCF3, S(O)2CF3, NO2, en donde alquilo y alquileno son no sustituidos o mono-, di- o trisustituidos con F; R6, R7, R8 y R9 son, de modo independiente, H, alquilo C1-6, alquilenC0-6-cicloalquiloC3-6, alquilenC0-6-ariloC6-14, alquilenC0-6- heteroariloC5-15, alquilenC0-6-heterocicloalquiloC5-15, alquilenC0-6-heterocicloalqueniloC3-15, en donde alquilo, alquileno y cicloalquilo no son sustituidos o son mono-, di- o trisustituidos con halogeno, alquilo C1-6, alquilenCO-6-O-alquilenC0-6- H, CF3, OCF3, CN, CO-alquiloC1-6, COO-alquiloC1-6, CON(alquilenC0-6-H)(alquilenC0-6-H), S(O)malquiloC1-6, y en donde arilo, cicloalquilo, heterocicloalquilo, heterocicloalquenilo y heteroarilo no son sustituidos o son mono-, di- o trisustituidos con halogeno, CF3, alquilo C1-6 y alquilen C0-4-O-alquilenC0-4-H; y en donde al menos un par de R6 y R7, R8 y R9 o R7 y R8 junto con los átomos de C a los que están conectados forman un cicloalquilo C3-12, un heterocicloalquilo C3-9 o un heterocicloalquenilo C3-9, en donde cicloalquilo, heterocicloalquilo y heterocicloalquenilo no son sustituidos o son mono-, di- o trisustituidos con halogeno, CF3, alquilo C1-6 y alquilenC0-4-O-alquilenC0-4-H; m es 0, 1, 2; en todas sus formas estereoisomeros, enantiomeros, y sus mezclas en cualquier relacion, y sus sales fisiologicamente aceptables y formas tautoméricas.
ARP060104363A 2005-10-06 2006-10-04 N-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas con actividad antagonista de receptores ppardelta o ppardelta y ppargamma AR057145A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05021785 2005-10-06
PCT/EP2006/009301 WO2007039175A1 (en) 2005-10-06 2006-09-26 N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
AR057145A1 true AR057145A1 (es) 2007-11-21

Family

ID=45219047

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104363A AR057145A1 (es) 2005-10-06 2006-10-04 N-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas con actividad antagonista de receptores ppardelta o ppardelta y ppargamma

Country Status (17)

Country Link
US (1) US7858647B2 (es)
EP (1) EP1937657A1 (es)
JP (1) JP2009510147A (es)
KR (1) KR20080050468A (es)
CN (1) CN101282951A (es)
AR (1) AR057145A1 (es)
AU (1) AU2006299089A1 (es)
BR (1) BRPI0616800A2 (es)
CA (1) CA2624681A1 (es)
IL (1) IL190461A0 (es)
MA (1) MA29809B1 (es)
NO (1) NO20081681L (es)
RU (1) RU2008113211A (es)
TW (1) TW200800929A (es)
UY (1) UY29846A1 (es)
WO (1) WO2007039175A1 (es)
ZA (1) ZA200801987B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2054397B1 (en) 2006-08-16 2015-10-07 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
EP2054056A4 (en) * 2006-08-16 2010-08-25 J David Gladstone Inst A Testa SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP2566853B1 (en) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
MX347889B (es) 2010-09-03 2017-05-17 Forma Tm Llc * Compuestos y composiciones novedosos para la inhibición de nampt.
CN102276554B (zh) * 2011-06-28 2013-10-30 四川大学 4-（（2-氨基-5-巯基-1,3,4-噻二唑）-甲基）-苯甲酰胺衍生物及其制备方法和用途
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
MD3986890T3 (ro) 2019-06-18 2025-07-31 Pfizer Derivați de benzizoxazol sulfonamidă

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
US7538135B2 (en) * 2003-07-08 2009-05-26 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds

Also Published As

Publication number Publication date
JP2009510147A (ja) 2009-03-12
IL190461A0 (en) 2008-11-03
UY29846A1 (es) 2007-05-31
US20090054494A1 (en) 2009-02-26
BRPI0616800A2 (pt) 2011-06-28
CN101282951A (zh) 2008-10-08
KR20080050468A (ko) 2008-06-05
EP1937657A1 (en) 2008-07-02
TW200800929A (en) 2008-01-01
WO2007039175A1 (en) 2007-04-12
MA29809B1 (fr) 2008-09-01
RU2008113211A (ru) 2009-10-10
US7858647B2 (en) 2010-12-28
NO20081681L (no) 2008-04-29
AU2006299089A1 (en) 2007-04-12
CA2624681A1 (en) 2007-04-12
ZA200801987B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
AR072041A1 (es) Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
AR072013A1 (es) Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas
AR057145A1 (es) N-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas con actividad antagonista de receptores ppardelta o ppardelta y ppargamma
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
DOP2014000303A (es) 7H-PIRROLO[2,3-d] PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2
BR112019003415A2 (pt) compostos de pirrolizina substituídos e usos dos mesmos
CL2009000975A1 (es) Compuestos derivados de quinuclidina, ligandos del receptor de acetilcolina a7; su composicion farmaceutica; su uso para el tratamiento de trastornos del sistema nervioso central, en especial afectivos y neurodegenerativos, enfermedades tales como esquizofrenia y alzheimer.
AR055060A1 (es) Derivados de n-(piridin-2-il)-sulfonamida
BR112015025140A2 (pt) 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem
HRP20230162T1 (hr) Heteroarilni inhibitori enzima pde4
PE20230156A1 (es) Sal de acido clorhidrico de (r)-4-(3-((s)-1-(4-amino-3-metil-1h pirazolo[3,4-d]pirimidin-1-il)etil)-5-cloro-2-etoxi-6-fluorofenil)pirrolidin-2-ona
RU2018136104A (ru) СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1,2,4]ТРИАЗОЛО[1,5- c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ A2А АНТАГОНИСТОВ
AR075243A1 (es) Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa
CR20150254A (es) Compuestos quimicos
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
AR046227A1 (es) Uso de tienopirimidinas en la preparacion de medicamentos para el tratamiento de tumores.
MX9202190A (es) 2-carboxiindoles substituidos que tienen actividad farmaceutica.
AR070187A1 (es) Derivados de dulfonamidas sustituidas
AR079271A1 (es) 3,6-diazabiciclo(3.1.1)heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina
AR072014A1 (es) Sulfonamidas con grupo de cabeza de heterociclo y oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas
AR078142A1 (es) Compuestos inhibidores heteroarilicos biciclicos de pde4, las composiciones farmaceuticas que los contienen y el uso de los mismos para la preparacion de medicamentos.
AR043430A1 (es) Derivados de diarilcicloalquilo, procesos para su preparacion y su uso como agentes farmaceuticos
MX2019007100A (es) Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
AR059625A1 (es) Aminoindanos propargilados, procesos para su preparacion, y usos de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal